Servier is paying $1.8 billion upfront for the oncology assets, with the total value of the deal potentially rising to $2 billion if Agios’ key pipeline candidate vorasidenib – a dual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback